
Peter Naredi, of ECCO, explores how a multi-dimensional approach is necessary to ensure that patients receive access to the most …

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

